Integral Molecular Announces Patent Allowance for Dengue Research Technology

July 17, 2014 Integral Molecular, a leader in membrane protein research, announces the issuance of a new composition patent protecting dengue reporter virus particles (RVPs). The invention relates to the company’s chimeric and codon-optimized flavivirus replicons, expression plasmids, and RVPs used for infectivity, neutralization, enhancement and structure-function studies of dengue virus (DENV) and its envelope protein (prM/E). U.S. Patent No …

The GAVI Alliance Board Have Approved a Framework That Will Support The Immunisation of an Additional 300 Million Children in Developing Countries

GAVI responds to Médecins Sans Frontières and civil society organisations’ open letter

June 20, 2014 The GAVI Alliance shares recently published MSF concerns about the slow implementation of the WHO recommendation to deliver a dose of hepatitis B vaccine immediately after birth. WHO estimates that hepatitis B causes around 260,000 deaths each year in GAVI-eligible countries, mostly in older men. Thanks to GAVI’s support for infant hepatitis B vaccination since 2000 – …

#wvcusa Hepatitis B Foundation – What’s new on the HBV vaccine watch?

  Today at the World Vaccine Congress, Dr Timothy Block, President at Hepatitis B Foundation presented about the Hepatitis B vaccine.   He also shared his views on: •    Waning immunity in people 20 years after vaccination and what are the implications •    Hear about the break throughs, escapes, following post natal dosing of newborns from chronic moms •    Discussing …